[1]樊 炜,马 玲,闫文慧,等.热休克蛋白90α在非小细胞肺癌患者血浆中的表达及应用价值[J].医学信息,2023,36(02):107-110.[doi:10.3969/j.issn.1006-1959.2023.02.021]
　FAN Wei,MA Ling,YAN Wen-hui,et al.Expression and Application Value of Heat Shock Protein 90 α in Plasma of Patients with Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(02):107-110.[doi:10.3969/j.issn.1006-1959.2023.02.021]
点击复制

热休克蛋白90α在非小细胞肺癌患者血浆中的表达及应用价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年02期
页码:
107-110
栏目:
论著
出版日期:
2023-01-15

文章信息/Info

Title:
Expression and Application Value of Heat Shock Protein 90 α in Plasma of Patients with Non-small Cell Lung Cancer
文章编号:
1006-1959（2023）02-0107-04
作者:
樊 炜; 马 玲; 闫文慧; 等
（大同市第二人民医院肿瘤医院检验科1，病理科2，山西 大同 037000）
Author(s):
FAN Wei; MA Ling; YAN Wen-hui; et al.
(Department of Laboratory1,Department of Pathology2,Datong Second People’s Hospital Cancer Hospital,Datong 037000,Shanxi,China)
关键词:
热休克蛋白90α; 非小细胞肺癌; 肿瘤标志物
Keywords:
Shock protein 90 α; Non-small cell lung cancer; Tumor markers
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.02.021
文献标志码:
A
摘要:
目的 探讨热休克蛋白90α（Hsp90α）在非小细胞肺癌患者血浆中的表达及应用价值。方法 选取2020年8月-2022年1月于我院经临床和病理确诊为非小细胞肺癌患者61例设为肺癌组，肺部良性疾病患者51例设为肺部良性疾病组，同期32例健康体检人员作为健康对照组。比较各组Hsp90α、癌胚抗原（CEA）、糖链抗原125（CA125）、细胞角质蛋白19片段（CYFRA21-1）、鳞状细胞癌抗原（SCCAg），并采用受试者工作特征（ROC）曲线分析各肿瘤标志物单独及联合检测的曲线下面积（AUC）及诊断非小细胞肺癌的敏感性、特异性。结果 肺癌组Hsp90α、CEA、CA125、SCCAg、CYFRA21-1高于肺部良性疾病组、健康对照组，差异有统计学意义（P＜0.05）；腺癌CEA、CA125水平高于鳞癌，CYFRA21-1、SCCAg水平低于鳞癌，差异有统计学意义（P＜0.05）；鳞癌和腺癌Hsp90α水平比较，差异无统计学意义（P＞0.05）；ROC曲线分析显示，血浆Hsp90α在肺癌诊断中的最佳临界值为101.99 ng/ml，其灵敏度为75.40%，特异度为74.50%；Hsp90α联合其他三项肿瘤标志物诊断非小细胞肺癌时AUC最大，为0.903。当使用特异性为90%时的值为阳性判定值，Hsp90α的敏感度为21.30%，而Hsp90α、CEA、SCC、CYFRA21-1四项联合使用的敏感度达到75.40%。结论 Hsp90α可作为非小细胞肺癌辅助诊断的血清标志物之一，与其他标志物联合检测可显著提高非小细胞肺癌的检出率，在非小细胞肺癌的早期诊断中有重要的临床价值。
Abstract:
Objective To investigate the expression and application value of heat shock protein 90α (Hsp90α) in plasma of patients with non-small cell lung cancer.Methods From August 2020 to January 2022, 61 patients with non-small cell lung cancer diagnosed by clinical and pathological diagnosis in our hospital were selected as lung cancer group, 51 patients with benign lung disease were selected as benign lung disease group, and 32 healthy people were selected as healthy control group. Hsp90α, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), cytokeratin 19 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCCAg) were compared among groups. The receiver operating characteristic (ROC) curve was used to analyze the area under the curve (AUC) of each tumor marker alone and combined detection and the sensitivity and specificity of diagnosis of non-small cell lung cancer.Results The levels of Hsp90α, CEA, CA125, SCCAg and CYFRA21-1 in lung cancer group were significantly higher than those in benign disease group and healthy control group (P<0.05). The levels of CEA and CA125 in adenocarcinoma were higher than those in squamous cell carcinoma, and the levels of CYFRA21-1 and SCCAg were lower than those in squamous cell carcinoma group (P<0.05), but there was no significant difference in the level of Hsp90α between squamous cell carcinoma and adenocarcinoma (P>0.05). ROC curve analysis showed that the optimal critical value of plasma Hsp90α in the diagnosis of lung cancer was 101.99 ng/ml, with a sensitivity of 75.40% and a specificity of 74.50%. The AUC of Hsp90α combined with other three tumor markers in the diagnosis of non-small cell lung cancer was the largest, which was 0.903. When the specificity was 90%, the sensitivity of Hsp90α was 21.30%, while the sensitivity of Hsp90α, CEA, SCC and CYFRA21-1 was 75.40%.Conclusion Hsp90 α can be used as one of the markers for the auxiliary diagnosis of non-small cell lung cancer. Combined with other markers, it can significantly improve the detection rate of non-small cell lung cancer, and has important clinical value in the early diagnosis of non-small cell lung cancer.

参考文献/References:

[1]Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.[2]刘苗苗.基于NGS对肺癌组织与血液肿瘤相关基因突变检测临床病理意义及一致性评价的研究[D].西安:空军军医大学,2019.[3]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[4]Mittal S,Rajala MS.Heat shock proteins as biomarkers of lung cancer[J].Cancer Biol Ther,2020,21(6):477-485.[5]Rong B,Yang S.Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments[J].Int J Oncol,2018,52(2):321-336.[6]Wang XF,Song XM,Zhuo W,et al.The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy[J].Proc Natl Acad Sci U S A,2009,106(50):21288-21293.[7]Travis WD,Brambilla E,Nicholson AG,et al.The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic,Clinical and Radiologic Advances Since the 2004 Classification[J].J Thorac Oncol,2015,10(9):1243-1260.[8]Ko JC,Chen JC,Chen TY,et al.Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells[J].Toxicology,2019,417:54-63.[9]Park SE,Kim DE,Kim MJ,et al.Vorinostat enhances gefitinib induced cell death through reactive oxygen species dependent cleavage of HSP90 and its clients in non small cell lung cancer with the EGFR mutation[J].Oncol Rep,2019,41(1):525-533.[10]Saini J,Sharma PK.Clinical,Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer[J].Curr Drug Targets,2018,19(13):1478-1490.[11]Hyun SY,Le HT,Nguyen CT,et al.Development ofa novel HSP90 inhibitor NCT- 50 as a potential anticanceragent for the treatment of non-small cell lung cancer[J].Sci Rep,2018,8(1):13924.[12]Alarcon SV,Mollapour M,Lee MJ,et al.Tumor-intrinsicand tumor- extrinsic factors impacting HSP90- targeted therapy[J].Current Molecular Medicine,2012,12(9):1125-1141.[13]Wei Q,Ning JY,Dai X,et al.Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells[J].Eur J Med Chem,2018,10(145):551-558.[14]张庆辉,侯森,唐新亚,等.血浆热休克蛋白90α在肝癌诊断及预后评估中的价值分析[J].癌症进展,2019,17(24):2965-2968.[15]姜源,舒静,陈敏.血浆热休克蛋白90α在肺癌中表达及临床价值[J].重庆医学,2018,47(35):4500-4503.[16]中华医学会呼吸病学分会肺癌学组,中国肺癌防治联盟专家组.肺结节诊治中国专家共识[J].中华结核和呼吸杂志,2018,41(10):763-771．[17]Yang Q,Zhang P,Wu R,et al.Identifying the Best Marker Combination in CEA,CA125,CY211,NSE,and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?[J].Dis Markers,2018,2018:2082840.[18]Li X,Asmitananda T,Gao L,et al.Biomarkers in the lung cancer diagnosis: a clinical perspective [J].Neoplasma,2012,59(5):500-507.[19]Su JM,Hsu YY,Lin P,et al.Nuclear Accumulation of Heat-shock Protein 90 Is Associated with Poor Survival and Metastasis in Patients with Non-small Cell Lung Cancer[J].Anticancer Res,2016,36(5):2197-203.[20]Wang Y,Seyed Barghi SM,Yang Y,et al.Value of HSP90α in Lung Cancer Diagnosis and Recurrence Prediction: A Cohort Study[J].Oncol Res Treat,2021,44(11):583-589.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(02):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(02):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(02):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(02):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(02):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(02):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01